Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Aerovance Raises $38 Million; Plans To Partner Phase IIb Asthma Drug In 2010

This article was originally published in The Pink Sheet Daily

Executive Summary

Financing will fund Phase IIb studies and formula enhancements for uncontrolled asthma compound; expects to partner drug in 2010.

You may also be interested in...



Bayer: Out of Trouble Come Opportunities

Bayer's respiratory diseases spin-out Aerovance shows how new opportunities are springing out of Europe's mid-sized firms, many of which are in transition.

Bayer Spins Off Respiratory Products To Aerovance

Former Bayer execs are forming the biotech firm with funding from Apex Partners. Aerovance's lead products are an IL4/13 receptor antagonist for severe asthma entering Phase II, and a recombinant therapeutic protein for chronic obstructive pulmonary disease and cystic fibrosis planned for Phase I.

Big Pharma Still Hopeful For Next Mega Drugs To Supplement Sales

Drug makers need to continue investing in early-stage research to unveil the next $1 billion-plus drug, panelists at the Argyle conference agree.

Topics

UsernamePublicRestriction

Register

PS069383

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel